Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/jid.2015.178 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual-Tumour Mouse Melanoma Model.
Exp Dermatol
September 2025
UMR1240 INSERM, Université Clermont Auvergne, Clermont-Ferrand, France.
The combination of melanin-targeted radionuclide therapy (TRT) and immunotherapy offers potential in overcoming melanoma resistance to conventional therapies. Studying the potential abscopal effect induced by TRT is essential to evaluate such combination. We develop here a preclinical murine model comprising a target (pigmented) and non-target (non-pigmented) tumour to study the abscopal effect induced by melanin-TRT in melanoma.
View Article and Find Full Text PDFA 5-week low-dose prednisolone regimen for progressive vitiligo: efficacy and safety in a single-center cohort study.
Ann Med
December 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
Background: Progressive vitiligo lacks standardized glucocorticoid regimens, with prolonged treatments often causing adverse effects. This study evaluated a novel 5-week low-dose prednisolone strategy (0.5 mg/kg/day, tapered weekly) to balance efficacy and safety.
View Article and Find Full Text PDFImmune and biological changes during treatment in patients with non-segmental vitiligo and their relation to repigmentation.
J Invest Dermatol
August 2025
Amsterdam University Medical Center, Department of Dermatology; Netherlands Institute for Pigment Disorders; Cancer Center Amsterdam; Amsterdam institute for Immunology and Infectious diseases, the Netherlands. Electronic address:
The treatment of non-segmental vitiligo (NSV) remains challenging and poorly understood. The aim of this study was to evaluate protein differences in lesional and non-lesional skin and changes of cellular and proteomic markers early in treatment in lesional skin and blood in relation to clinical response. This prospective exploratory study was conducted in 30 NSV patients, 11 starting with standard-of-care topical therapy and 19 in combination with narrowband (NB)-UVB phototherapy.
View Article and Find Full Text PDFEfficacy of Superoxide Dismutase in the Treatment of Vitiligo: A Systematic Review.
Cureus
July 2025
Dermatology, Centro Dermatológico "Dr. Ladislao de la Pascua", IMSS para el Bienestar, Mexico City, MEX.
Vitiligo is a chronic autoimmune skin condition characterized by the progressive loss of melanocytes, resulting in well-defined hypopigmented or achromic patches. Oxidative stress is believed to play a role in its pathogenesis, and superoxide dismutase (SOD), an antioxidant enzyme, has emerged as a potential therapeutic option. This systematic review aimed to evaluate the efficacy of oral or topical SOD, used either alone or in combination with other interventions, in the treatment of vitiligo.
View Article and Find Full Text PDFObservational study on postoperative JAK inhibitor and corticosteroid therapy following non-cultured epidermal cell suspension transplantation in stable vitiligo patients.
J Dermatolog Treat
December 2025
Department of Dermatology, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital; Medical Center of Soochow University), Suzhou, China.
Objective: To compare the efficacy and safety of oral corticosteroids and JAK inhibitors as adjunctive treatments following non-cultured epidermal cell suspension (NCES) transplantation in patients with stable vitiligo.
Methods: Data were collected from 12 patients with stable vitiligo who underwent NCES transplantation at the Fourth Affiliated Hospital of Soochow University between June 2023 and December 2024. Postoperatively, 36 lesions (from 7 patients) were treated with oral corticosteroids, and 34 lesions (from 5 patients) with upadacitinib, totaling 70 vitiligo lesions evaluated.